These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 4829901)

  • 1. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide and beyond: some recommendations regarding public policies toward the ethical drug industry.
    Schifrin LG
    Int J Health Serv; 1974; 4(1):147-55. PubMed ID: 4829893
    [No Abstract]   [Full Text] [Related]  

  • 3. Present attitudes of governmental drug regulatory agencies.
    Noel PR
    Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283
    [No Abstract]   [Full Text] [Related]  

  • 4. Minimum acceptable requirements for introduction and marketing of drugs.
    Lasagna L
    Drugs; 1974; 7(6):409-13. PubMed ID: 4422210
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs on the market.
    JAMA; 1970 Feb; 211(7):1177. PubMed ID: 5466970
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial: Bioavailability, bioequivalence and bias.
    Leopold IH
    Am J Ophthalmol; 1975 Mar; 79(3):518. PubMed ID: 1122003
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonprescription drugs: an overview.
    Hodes B
    Int J Health Serv; 1974; 4(1):125-30. PubMed ID: 4829892
    [No Abstract]   [Full Text] [Related]  

  • 8. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
    Levy E
    Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
    [No Abstract]   [Full Text] [Related]  

  • 9. Medicolegal aspects of drug testing and systems of institutional review.
    Am J Cardiol; 1974 Oct; 34(4):482-4. PubMed ID: 4606800
    [No Abstract]   [Full Text] [Related]  

  • 10. A perspective on US drug reimportation.
    Choudhry NK; Detsky AS
    JAMA; 2005 Jan; 293(3):358-62. PubMed ID: 15657329
    [No Abstract]   [Full Text] [Related]  

  • 11. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical drugs-the good and the not so good: together, we can make it better.
    Campbell AW
    Altern Ther Health Med; 2014; 20(1):9-11. PubMed ID: 24445351
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 14. CONTROL OF DRUG TOXICITY IN THE UNITED STATES OF AMERICA.
    WESTON JK; WESTON K
    Practitioner; 1965 Jan; 194():16-21. PubMed ID: 14259685
    [No Abstract]   [Full Text] [Related]  

  • 15. The Food and Drug Administration's requirements for approval of new dental drugs.
    Gilkes CC
    Symp Pharmacol Ther Toxicol Group; 1975 Apr; ():5-12. PubMed ID: 1064180
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug metabolites in safety testing.
    Hastings KL; El-Hage J; Jacobs A; Leighton J; Morse D; Osterberg RE
    Toxicol Appl Pharmacol; 2003 Jul; 190(1):91-2;author reply 93-4. PubMed ID: 12831788
    [No Abstract]   [Full Text] [Related]  

  • 17. Today's dilemma--will drugs work?
    Dowling HF
    J Am Pharm Assoc; 1971 Jun; 11(6):331-3. PubMed ID: 5118797
    [No Abstract]   [Full Text] [Related]  

  • 18. The United States Pharmacopeia. Its value to the professions.
    Heller WM
    JAMA; 1970 Jul; 213(4):576-9. PubMed ID: 4914287
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological and safety aspects of existing requirements and regulations when introducing a new drug.
    Kramer M
    Arzneimittelforschung; 1974 Apr; 24(4):504-8. PubMed ID: 4408328
    [No Abstract]   [Full Text] [Related]  

  • 20. Research at the interface of industry, academia and regulatory science.
    Mattes WB; Walker EG; Abadie E; Sistare FD; Vonderscher J; Woodcock J; Woosley RL
    Nat Biotechnol; 2010 May; 28(5):432-3. PubMed ID: 20458309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.